Menu
Search
|

Menu

Close
X

Ultragenyx Pharmaceutical Inc RARE.OQ (NASDAQ Stock Exchange Global Select Market)

66.16 USD
+4.37 (+7.07%)
As of Oct 16
chart
Previous Close 61.79
Open 62.15
Volume 247,068
3m Avg Volume 186,471
Today’s High 66.61
Today’s Low 61.18
52 Week High 90.95
52 Week Low 41.68
Shares Outstanding (mil) 42.46
Market Capitalization (mil) 2,305.92
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY18
23
FY17
3
FY16
0
FY15
0
EPS (USD)
FY18
-0.438
FY17
-5.479
FY16
-6.201
FY15
-3.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.69
Price to Sales (TTM)
vs sector
19,878.61
5.82
Price to Book (MRQ)
vs sector
5.37
4.90
Price to Cash Flow (TTM)
vs sector
--
22.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.96
LT Debt to Equity (MRQ)
vs sector
0.00
12.63
Return on Investment (TTM)
vs sector
-62.70
14.32
Return on Equity (TTM)
vs sector
-63.52
16.04

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Emil Kakkis
President, Chief Executive Officer, Director, Since
Salary: $638,115.00
Bonus: --
Shalini Sharp
Chief Financial Officer, Executive Vice President, Since 2016
Salary: $455,785.00
Bonus: --
Wladimir Hogenhuis
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Karah Parschauer
Executive Vice President, General Counsel, Since 2016
Salary: $175,000.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

60 Leveroni Ct
NOVATO   CA   94949-5746

Phone: +1415.4838800

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

SPONSORED STORIES